Bassand              J.P., Hamm C.W., Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST- segment elevation acute coronary syndromes // Eur. Heart J. - 2007. - Vol. 28. - P. 1598-1660.
Bassand              J.P. Bleeding and transfusion in acute coronary syndromes a shift in the paradigm // Heart. - 2008. - Vol. 94. - P. 661-666.
Clappers              N., Brouwer M.A., Verheugt F.W. Antiplatelet treatment for coronary heart disease // Heart. - 2007. - Vol. 93. - P. 258-265.
Graham              I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary // Eur. Heart J. - 2007. - Vol. 28. - P. 2375-2414.
Hillis              L.D., Lange R.A. Optimal management of acute coronary syndromes // N. Engl. J. Med. - 2009. - Vol. 360. - P. 2237-2240.
Korff              S., Katus H.A., Giannitsis E. Differential diagnosis of elevated troponins // Heart. - 2006. - Vol. 92.
P. 987-993.
Mollmann              H., Nef H., Elsasser A. et al. Stem cells in myocardial infarction from bench to bedside // Heart. - 2009. - Vol. 95. - P. 508-514.
Thygesen              K., Alpert J.S., White H.D. Universal definition of myocardial infarction // Eur. Heart J. - 2007.
Vol. 28. - P. 2525-2538.
Van              de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology // Eur. Heart J. - 2008. - Vol. 29. - P. 2909-2945.
White              H.D., Chew D.P. Acute myocardial infarction // Lancet. - 2008. - Vol. 372. - P. 570-584.
11 .Wiviott S. Antiplatelet therapy in ischemic heart disease, 2009. Chichester. Wiley-Blackwell.
СПИСОК ЛИТЕРАТУРЫ
Thygesen              K., Alpert J.S., White H.D. Universal definition of myocardial infarction // Eur. Heart J. - 2007. - Vol. 28. - P. 2525-2538.
Hamm              C.W., Bertrand M., Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines // Lancet. -
- Vol. 358. - P. 1533-1538.
Rationale              and design of the GRACE (Global Registry of Acute Coronary Events) Project. a multinational registry of patients hospitalized with acute coronary syndromes // Am. Heart J. - 2001. - Vol. 141. - P. 190-199.
Hochholzer              W. et al. New definition of myocardial infarction: impact on long-term mortality // Am. J.
Med. - 2008. - Vol. 121. - P. 399-405.
AHA.              Heart and Stroke Statistical Update. 2001, American Heart Association: Dallas TX.
Coronary              Heart Disease Statistics. 2004, London: British Heart Foundation.
Birkhead              J.S. et al. Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP) // Heart. - 2004. - Vol. 90. - P. 1004-1009.
Eagle              K.A. et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry // JAMA. - 2004. - Vol. 291. - P. 27272733.
Fox              K.A. et al. Management of acute coronary syndromes. Variations in practice and outcome. - findings from the Global Registry of Acute Coronary Events (GRACE) // Eur. Heart J. - 2002. - Vol. 23. -
P. 1177-1189.
Hasdai              D. et al. Cardiac biomarkers and acute coronary syndromes-the Euro Heart Survey of Acute Coronary Syndromes Experience // Eur. Heart J. - 2003. - Vol. 24. - P. 1189-1194.
11 .Hasdai D. et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. - the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS) // Eur. Heart J. - 2002. - Vol. 23. - P. 1190-1201.
Hoekstra              J.W. et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative // Acad. Emerg. Med. - 2002. - Vol. 9. - P. 11461155.
Lev              E.I. et al. Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns // Am. J. Cardiol. - 2003. - Vol. 91. - P. 224
227.
14.Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival // JAMA. - 2001. - Vol. 285. - P. 430-436.
15.Stenestrand U., Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study // Lancet. - 2002. - Vol. 359. - P. 1805-1811.
Goldberg              R.J. et al. Recent changes in attack and survival rates of acute myocardial infarction (1975. through 1981). The Worcester Heart Attack Study // JAMA. - 1986. - Vol. 255. - P. 2774-2779.
Bata              I.R. et al. Trends in the incidence of acute myocardial infarction between 1984. and 1993. - The Halifax County MONICA Project // Can. J. Cardiol. - 2000. - Vol. 16. - P. 589-595.
Fox              K.A. et al. The ENACT study. a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment // Eur. Heart J. - 2000. - Vol. 21. - P. 1440-1449.
Furman              M.I. et al. Twenty-two year (1975. to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community- wide perspective // J. Am. Coll. Cardiol. - 2001. - Vol. 37. - P. 1571-1580.
van              der Pal-de Bruin K.M. et al. The incidence of suspected myocardial infarction in Dutch general practice in the period 1978-1994 // Eur. Heart J. - 1998. - Vol. 19. - P. 429-4234.
.Savonitto S. et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes // JAMA. - 1999. - Vol. 281. - P. 707-713.
Tunstall-Pedoe              H. et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations // Lancet.
2000. - Vol. 355. - P. 688-700.
Marques-Vidal              P. et al. Incidence, recurrence, and case fatality rates for myocardial infarction in southwestern France 1985;to 1993 // Heart. - 2000. - Vol. 84. - P. 171-175.
Abrahamsson              P. et al. Improved long-term prognosis after myocardial infarction 1984-1991 // Eur. Heart J. - 1998. - Vol. 19. - P. 1512-1517.
Capewell              S., Morrison C.E., McMurray J.J. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975. and 1994 // Heart. - 1999. - Vol. 81. - P. 380-386.
Liu              J.L. et al. The economic burden of coronary heart disease in the UK // Heart. - 2002. - Vol. 88. - P. 597-603.
Guilbert              J.J. The world health report 2002. - reducing risks, promoting healthy life. Educ Health (Abingdon). - 2003. - Vol. 16. - P. 230.
Fox              K.A. et al. Interventional versus conservative treatment for patients with unstable angina or non- ST-elevation myocardial infarction: the British Heart Foundation RITA 3. randomised trial. Randomized Intervention Trial of unstable Angina // Lancet. - 2002. - Vol. 360. -
P. 743-751.
Elsaesser              A., Hamm C.W. Acute coronary syndrome: the risk of being female // Circulation. - 2004. - Vol. 109. - P. 565-567.
Behavioral              Risk Factor Surveillance System. in Centers for Disease Control and Prevention. 2001, CDC: Bethesda MD.
31 .Weiss R. et al. Obesity and the metabolic syndrome in children and adolescents // N. Engl. J. Med. -
- Vol. 350. - P. 2362-2374.
Falk              E., Shah P.K., Fuster V. Atherothrombosis and thrombosis-prone plaques., In Fuster V,
Alexander R, O’Rourke R (eds.) Hurst’s The Heart, 2004, McGraw-Hill: new York. p. 1123-1139.
Graham              I. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) // Eur. J. Cardiovasc. Prev. Rehabil. - 2007. - Vol. 14. Suppl 2: E1-40.
Gaede              P. et al. Multifactorial intervention and cardiovascular disease in patients with type
diabetes // N. Engl. J. Med. - 2003. - Vol. 348. - P. 383-393.
Kannel              W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment // JAMA. - 1996.
Vol. 275. - P. 1571-1576.
Assmann              G., Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease // Am. Heart J. - 1988. - Vol. 116. - P. 1713-1724.
Lewington              S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61. prospective studies // Lancet. - 2002. - Vol. 360. - P. 1903-1913.
Ninomiya              J.K. et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey // Circulation. - 2004. - Vol. 109. - P. 42-46.
Baigent C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056. participants in 14. randomised trials of statins // Lancet. - 2005. - Vol. 366. - P. 12671278.
40.Sever P.S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial // Lancet. - 2003. - Vol. 361. - P. 1149-1158.
41 .Martyn C.N., Barker D.J., Osmond C. Mothers’ pelvic size, fet al growth, and death from stroke and coronary heart disease in men in the UK // Lancet. - 1996. - Vol. 348. - P. 1264-1268.
Barker              D.J. F. et al. origins of coronary heart disease // BMJ. - 1995. - Vol. 311. - P. 171-174.
Edwards              C.R. et al. Dysfunction of placental glucocorticoid barrier: link between fet al environment and adult hypertension? // Lancet. - 1993. - Vol. 341. - P. 355-357.
Nyirenda              M.J. et al. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring // J. Clin. Invest. - 1998. - Vol. 101. - P. 2174-2181.
Yusuf              S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52. countries (the INTERHEART study): case-control study // Lancet. - 2004. - Vol. 364. - P. 937-952.
Lusis              A.J. Atherosclerosis // Nature. - 2000. - Vol. 407. - P. 233-241.
47.Samani N.J. et al. Genomewide association analysis of coronary artery disease // N. Engl. J. Med. - 2007. - Vol. 357. - P. 443-453.
Genome-wide              association study of 14,000. cases of seven common diseases and 3,000. shared controls // Nature. - 2007. - Vol. 447. - P. 661-678.
Davies              M.J. The pathophysiology of acute coronary syndromes // Heart. - 2000. - Vol. 83. - P. 361366.
Glass              C.K., Witztum J.L. Atherosclerosis. the road ahead // Cell. - 2001. - Vol. 104. - P. 503-516.
.P. Current concepts of the pathogenesis of the acute coronary syndromes // Circulation. - 2001. - Vol. 104. - P. 365-372.
Burke              A.P. et al. 34th Bethesda Conference: Task force #2-What is the pathologic basis for new atherosclerosis imaging techniques? // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1874-1886.
Hoffmann              U., Brady T.J., Muller J. Cardiology patient page. Use of new imaging techniques to screen for coronary artery disease // Circulation. - 2003. - Vol. 108: e50-53.
Moncada              S., Higgs A. The L-arginine-nitric oxide pathway // N. Engl. J. Med. - 1993. - Vol. 329. - P. 2002-2012.
Mather              K., Anderson T.J., Verma S. Insulin action in the vasculature: physiology and pathophysiology // J. Vasc. Res. - 2001. - Vol. 38. -
P. 415-422.
56.Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease // Circulation. - 2000. - Vol. 101. - P. 1899-1906.
57.Fichtlscherer S., Breuer S., Zeiher A.M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the “vulnerable” patient // Circulation. - 2004. - Vol. 110. - P. 1926-3192.
58.Stary H.C. et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association // Circulation. - 1995. - Vol. 92. - P. 1355-1374.
59.Schaar J.A. et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17. and 182:003, Santorini, Greece // Eur. Heart J. - 2004. - Vol. 25. - P. 1077-1082.
60.Naghavi M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part I // Circulation. -
2003. - Vol. 108. - P. 1664-1672.
61 .Naghavi M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part II // Circulation. - 2003. - Vol. 108. - P. 1772-1778.
Varnava              A.M., Mills P.G., Davies M.J. Relationship between coronary artery remodeling and plaque vulnerability // Circulation. - 2002. - Vol. 105. - P. 939-943.
Vink              A. et al. Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors? // J. Am. Coll. Cardiol. - 2001. - Vol. 38. - P. 718-723.
Guyton              J.R. Phospholipid hydrolytic enzymes in a ‘cesspool’ of arterial intimal lipoproteins: a mechanism for atherogenic lipid accumulation // Arterioscler. Thromb. Vasc. Biol. - 2001. - Vol. 21. - P. 884-846.
Naruko              T. et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes // Circulation. -
- Vol. 106. - P. 2894-2900.
Kaartinen              M. et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 606-612.
Kolodgie              F.D. et al. Intraplaque hemorrhage and progression of coronary atheroma // N. Engl. J. Med.
2003. - Vol. 349. - P. 2316-2325.
68.Schwartz S.M., Virmani R., Rosenfeld M.E. The good smooth muscle cells in atherosclerosis // Curr. Atheroscler. Rep. - 2000. - Vol. 2. - P. 422-429.
69.Beckman J.A. et al. Relationship of clinical presentation and calcification of culprit coronary artery stenoses // Arterioscler. Thromb. Vasc. Biol. - 2001. - Vol. 21. - P. 1618-1622.
70.Sangiorgi G. et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723. coronary artery segments using nondecalcifying methodology // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 126-133.
71.Servoss S.J., Januzzi J.L., Muller J.E. Triggers of acute coronary syndromes // Prog. Cardiovasc. Dis.
2002. - Vol. 44. - P. 369-380.
Mann              J., Davies M.J. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption // Heart. - 1999. - Vol. 82. - P. 265-268.
Falk              E. Widespread targets for friendly fire in acute coronary syndromes // Circulation. - 2004. - Vol. 110. - P. 4-6.
Virmani              R. et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - P. 1262-1275.
Tedgui              A., Mallat Z. Apoptosis as a determinant of atherothrombosis // Thromb. Haemost. - 2001. - Vol. 86. - P. 420-426.
Bogdanov              V.Y. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein // Nat. Med. - 2003. - Vol. 9. -
P. 458-462.
Fernandez-Ortiz              A. et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture // J. Am. Coll. Cardiol. - 1994. - Vol. 23. -
P. 1562-1569.
Tabardel              Y. et al. Corticosteroids increase blood interleukin-10. levels during cardiopulmonary bypass in men // Surgery. - 1996. - Vol. 119. - P. 76-80.
Ardissino              D. et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques // Lancet. - 1997. - Vol. 349. - P. 769-771.
Ruggeri              Z.M. Platelets in atherothrombosis // Nat. Med. - 2002. - Vol. 8. - P. 1227-1234.
81 .Falk E, Thuesen L. Pathology of coronary microembolisation and no reflow // Heart. - 2003. - Vol. 89. - P. 983-985.
Reimer              K.A., Jennings R.B. The “wavefront phenomenon” of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow // Lab. Invest. - 1979. - Vol. 40. - P. 633-644.
Kloner              R.A. Does reperfusion injury exist in humans? // J. Am. Coll. Cardiol. - 1993. - Vol. 21. - P. 537545.
Reffelmann              T., Kloner R.A. The “no-reflow” phenomenon: basic science and clinical correlates //
Heart. - 2002. - Vol. 87. - P. 162-168.
Volmink              J.A. et al. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group // Heart. - 1998. - Vol. 80. - P. 40-44.
Terkelsen              C.J. et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort // Eur. Heart J. - 2005. - Vol. 26. - P. 18-26.
Bahit              M.C., Granger C.B., Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment // Am. Heart J. - 2002. - Vol. 143. - P. 205-216.
Bogaty              P. et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina // Circulation. - 2001. - Vol. 103. - P. 3062-3068.
Hemingway              H. et al. Prospective validity of measuring angina severity with Canadian Cardiovascular Society class. The ACRE study // Can. J. Cardiol. - 2004. - Vol. 20. - P. 305-309.
Culic              V. et al. Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors // Am. Heart J. - 2002. - Vol. 144. - P. 1012-1017.
.Canto J.G. et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris // Am. J. Cardiol. - 2002. - Vol. 90. - P. 248-253.
Braunwald              E. Unstable angina. A classification // Circulation. - 1989. - Vol. 80. - P. 410-414.
Lee              T.H. et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients // Arch Intern Med. - 1985. - Vol. 145. - P. 65-69.
Bean              W.B. Masquerades of myocardial infarction // Lancet. - 1977. - Vol. 1. - P. 1044-1046.
Cannon              C.P. et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia // J. Am. Coll. Cardiol. - 1997. - Vol. 30. - P. 133-140.
van              Miltenburg-van Zijl A.J. et al. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris // J. Am. Coll. Cardiol. - 1995. - Vol. 25. - P. 1286-1292.
Hamm              C.W., Braunwald E. A classification of unstable angina revisited. // Circulation. - 2000. - Vol. 102. - P. 118-122.
Fesmire              F.M. et al. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain // Ann. Emerg. Med. - 1998. - Vol. 31. - P. 3
11.
Holmvang              L. et al. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment // J. Am. Coll.
Cardiol. -
- Vol. 41. - P. 905-915.
Hyde              T.A. et al. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression // Am. J. Cardiol. - 1999. - Vol. 84. - P. 379-385.
Kaul              P. et al. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network // J. Am. Coll. Cardiol. - 2001. -
Vol. 38. - P. 64-71.
Nyman              I. et al. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group // J. Intern. Med. - 1993. - Vol. 234. - P. 293
301.
de              Zwaan C. et al. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery // Am. Heart J. - 1989. - Vol. 117. - P. 657-665.
McCarthy              B.D., Wong J.B., Selker H.P. Detecting acute cardiac ischemia in the emergency department: a review of the literature // J. Gen. Intern. Med. - 1990. - Vol. 5. - P. 365-373.
Moon              J.C. et al. The pathologic basis of Q-wave and non-Q-wave myocardial infarction: a cardiovascular magnetic resonance study // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 554-560.
Rouan              G.W. et al. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study) // Am. J. Cardiol. - 1989. - Vol. 64. - P. 1087-1092.
Pozen              M.W. et al. A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart disease. A prospective multicenter clinical trial // N. Engl. J. Med. - 1984. - Vol. 310. -
P. 1273-1278.
Apple              F.S. et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome // Clin. Chem. - 2005. - Vol. 51. - P. 810-824.
Falk              E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion // Circulation. - 1985. - Vol. 71. - P. 699-708.
Davies              M.J. et al. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death // Circulation. - 1986. - Vol. 73. - P. 418-427.
Katus              H.A. et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T // Clin. Chem. - 1992. - Vol. 38. - P. 386-393.
Gerhardt              W. et al. S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-creatine kinase isoenzyme MB // Clin. Chem. - 1991. - Vol. 37. - P. 14051411.
Hamm              C.W. et al. The prognostic value of serum troponin T in unstable angina // N. Engl. J. Med. - 1992. - Vol. 327. - P. 146-150.
Wu              A.H. et al. Prognostic value of cardiac troponin T in unstable angina pectoris // Am. J. Cardiol. - 1995. - Vol. 76. - P. 970-972.
Antman              E.M. et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes // N. Engl. J. Med. - 1996. - Vol. 335. - P. 1342-1349.
Lindahl              B., Venge P., Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group // Circulation. - 1996. - Vol. 93. - P. 1651-1657.
Hamm              C.W. et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I // N. Engl. J. Med. - 1997. - Vol. 337. - P. 1648-1653.
Heeschen              C. et al. Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I // Clin. Chem. - 1998. - Vol. 44. - P. 1925-1930.
Heeschen              C. et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3. AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial // J. Am. Coll. Cardiol. -
- Vol. 35. - P. 1535-1542.
Heeschen              C. et al. Cardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status // Eur. Heart J. - 2000. - Vol. 21. - P. 1159-1166.
Myocardial              infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction // Eur. Heart J. - 2000. - Vol. 21. - P. 1502-1513.
Newby              L.K. et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators // Circulation. - 1998. - Vol. 98. - P. 18531859.
Lindahl              B. et al. Noninvasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. FRISC Study Group // Am. J. Cardiol. - 1997. - Vol. 80. - P. 40E-44E.
Rao              SV, et al. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes // Am. J. Cardiol. - 2003. - Vol. 91. - P. 936-940.
Bassand              JP, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes // Eur. Heart J. - 2007. - Vol. 28. - P. 1598-1660.
Apple              F.S. et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines. Analytical issues for biomarkers of heart failure // Circulation. - 2007. - Vol. 116: e95-98.
Missov              E. et al. Cardiac troponin I in patients with hematologic malignancies // Coron. Artery Dis. - 1997. - Vol. 8. - P. 537-541.
Kobayashi              S. et al. Serum cardiac troponin T in polymyositis/dermatomyositis // Lancet. - 1992. - Vol. 340. - P. 726.
Turner              A., Tsamitros M., Bellomo R. Myocardial cell injury in septic shock // Crit. Care Med. - 1999. - Vol. 27. - P. 1775-1780.
130.Ooi D.S. et al. Cardiac troponin T predicts long-term outcomes in hemodialysis patients // Clin.
Chem. - 2001. - Vol. 47. - P. 412-417.
Wayand              D. et al. Cardiac troponin T and I in end-stage renal failure // Clin. Chem. - 2000. - Vol. 46. - P. 1345-1350.
Dierkes              J. et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease // Circulation. - 2000. - Vol. 102. - P. 1964-1969.
Apple              F.S. et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients a 1 - year outcomes analysis // Am. J. Kidney Dis. - 1997. - Vol. 29. - P. 399-403.
McLaurin              M.D. et al. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle // Clin. Chem. - 1997. - Vol. 43. - P. 976-982.
Wu              A.H., Feng Y.J. Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes // Eur. Heart J. - 1998. - Vol. 19(Suppl. N): n25-9.
Dean              K. Biochemistry of troponin, in Cardiac Markers, AH. Wu, Editor. 1998, Humana Press. Totowa. 193-204.
Ellis              K., Dreisbach A.W., Lertora J.L. Plasma elimination of cardiac troponin I in end-stage renal disease // South Med. J. - 2001. - Vol. 94. - P. 993-996.
Apple              F.S. et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease // Circulation. - 2002. - Vol. 106. - P. 2941-2945.
Aviles              R.J. et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction // N. Engl. J. Med. - 2002. - Vol. 346. - P. 2047-2052.
Weber              M., Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine // Heart. - 2006. - Vol. 92. - P. 843-849.
Goetze              J.P. et al. Acute myocardial hypoxia increases BNP gene expression // Faseb. J. - 2004. - Vol. 18. - P. 1928-1930.
Hama              N. et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction // Circulation. - 1995. - Vol. 92. - P. 1558-1564.
Weber              M. et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris // Am. Heart J. - 2004. - Vol. 148. - P. 612-620.
Kragelund              C. et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease // N. Engl. J. Med. - 2005. - Vol. 352. - P. 666-675.
Bibbins-Domingo              K. et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT- proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease // JAMA. -
2007. - Vol. 297. - P. 169-176.
Heeschen              C. et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes // Circulation. - 2004. - Vol. 110. - P. 3206-3212.
James              S.K. et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy // Circulation.
2003. - Vol. 108. - P. 275-281.
Jernberg              T. et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease // J. Am. Coll. Cardiol.
2003. - Vol. 42. - P. 1909-1916.
149.Omland T. et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes // Circulation. - 2002. -
Vol. 106. - P. 2913-2918.
Jernberg              T. et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation // J. Am. Coll. Cardiol. - 2002. - Vol. 40. - P. 437445.
de              Lemos J.A. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes // N. Engl. J. Med. -
- Vol. 345. - P. 1014-1021.
Bazzino              O. et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes // Eur. Heart J. - 2004. - Vol. 25. - P. 859-866.
Weber              M. et al. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 1188-1195.
Windhausen              F. et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy // Am. Heart J. - 2007. - Vol. 153. - P. 485-492.
Morrow              D.A. et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI
// J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1264-1272.
James              S.K. et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy // J. Am. Coll. Cardiol. - 2006. - Vol. 48. - P. 1146-1154.
157.Omland T. et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial // J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 205-214.
158.Calabro P., Willerson J.T., Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells // Circulation. - 2003. - Vol. 108. - P. 1930-1932.
159.Szmitko P.E. et al. New markers of inflammation and endothelial cell activation. Part I // Circulation. -
- Vol. 108. - P. 1917-1923.
Ridker              P.M. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men // N. Engl. J. Med. - 1997. -
Vol. 336. - P. 973-979.
Ridker              P.M. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // N. Engl. J. Med. - 2000. - Vol. 342. - P. 836-843.
Albert              M.A., Glynn R.J., Ridker P.M. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score // Circulation. - 2003. - Vol. 108. - P. 161-165.
Koenig              W. et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany // Circulation. -
- Vol. 109. - P. 1349-1353.
Danesh              J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease // N. Engl. J. Med. - 2004. - Vol. 350. - P. 1387-1397.
Danesh              J. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses // BMJ. - 2000. - Vol. 321. - P. 199-204.
Koenig              W. Update on C-reactive protein as a risk marker in cardiovascular disease // Kidney Int. Suppl. - 2003. - Vol. S58-61.
Ridker              P.M. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events // N. Engl. J. Med. - 2002. - Vol. 347. - P. 1557-1565.
Liuzzo              G. et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina // N. Engl. J. Med. - 1994. - Vol. 331. - P. 417-424.
Morrow              D.A. et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 1460-1465.
Haverkate              F. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group // Lancet. - 1997. - Vol. 349. - P. 462-466.
171.Sabatine M.S. et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18. (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18. trial)substudy // J. Am. Coll. Cardiol. - 2002. - Vol. 40. - P. 17611768.
Mueller              C. et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042. consecutive patients // Circulation. - 2002. -
Vol. 105. - P. 1412-1415.
Lindahl              B. et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease // N. Engl. J. Med. - 2000. - Vol. 343. - P. 1139-1147.
James              S.K. et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy // J. Am. Coll. Cardiol. -
2003. - Vol. 41. - P. 916-924.
Ridker              P.M. et al. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. - 2005. - Vol. 352. - P. 20-28.
Kinlay              S. et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study // Circulation. - 2003. - Vol. 108. - P. 1560-1566.
Ridker              P.M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events // N. Engl. J. Med. - 2001. - Vol. 344. - P. 1959-1965.
Nissen              S.E. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease //
N. Engl. J. Med. - 2005. - Vol. 352. -
P. 29-38.
Morrow              D.A. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes // Circulation. - 2007. - Vol. 115: e356-375.
Muller-Bardorff              M. et al. Development and characterization of a rapid assay for bedside determinations of cardiac troponin T // Circulation. -
1995. - Vol. 92. - P. 2869-2875.
Apple              F.S. et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction // Clin. Chem. -
- Vol. 45. - P. 199-205.
Panteghini              M., Pagani F. Characterization of a rapid immunochromatographic assay for simultaneous detection of high concentrations of myoglobin and CK-MB in whole blood // Clin. Chem. - 1996. -
Vol. 42(8. Pt 1). - P. 1292-1293.
Wu              A.H. et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases // Clin. Chem. - 1999. - Vol. 45. - P. 1104-1121.
Bertrand              M.E. et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. -
recommendations of the Task Force of the European Society of Cardiology // Eur. Heart J. - 2000. - Vol. 21. - P. 1406-1432.
Antman              E.M., Grudzien C., Sacks D.B. Evaluation of a rapid bedside assay for detection of serum cardiac troponin T // JAMA. - 1995. - Vol. 273. - P. 1279-1282.
186.Ohman E.M. et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries // Am.
J. Cardiol. - 1999. - Vol. 84. - P. 1281-1286.
187.Goldmann B.U. et al. Quantitative bedside testing of troponin T: is it equal to laboratory testing? The Cardiac Reader Troponin T (CARE T) study // Clin. Lab. - 2004. - Vol. 50. - P. 1-10.
188.Sylven C. et al. Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T // Am. Heart J. - 1998. - Vol. 135. - P. 677-683.
Gerhardt              W. et al. An improved rapid troponin T test with a decreased detection limit a multicentre study of the analytical and clinical performance in suspected myocardial damage // Scand. J. Clin. Lab Invest. - 1997. - Vol. 57. - P. 549-557.
Antman              E.M. et al. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 326-330.
Muller-Bardorff              M. et al. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing // Clin. Chem. - 1999. - Vol. 45. - P. 1002-1008.
192.Sabatine M.S. et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide // Circulation. - 2002. - Vol. 105. - P. 1760-1763.
Morrow              D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers // Circulation. - 2007. - Vol. 115. - P. 949-952.
Weber              M., Hamm C. Novel biomarkers-the long march from bench to bedside // Eur. Heart J. - 2008.
Vol. 29. - P. 1079-81.
Dirksen              M.S. et al. Cardiac multidetector-row computed tomography in patients with unstable angina // Am. J. Cardiol. - 2005. - Vol. 95. -
P. 457-461.
Cheitlin              M.D. et al. ACC/AHA/ASE 2003. guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the
Guidelines for the Clinical Application of Echocardiography) // Circulation. - 2003. - Vol. 108. - P. 1146-1162.
Kwong              R.Y. et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction // Circulation. - 2008. - Vol. 118. - P. 1011-1020.
Fox              K.A. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) // BMJ. - 2006. - Vol. 333. - P. 1091.
Granger              C.B. et al. Predictors of hospital mortality in the global registry of acute coronary events // Arch. Intern. Med. - 2003. - Vol. 163. - P. 2345-2353.
de              Araujo Goncalves P. et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS // Eur. Heart J. - 2005. - Vol. 26. - P. 865-872.
Antman              E.M. et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making // JAMA. - 2000. - Vol. 284. - P. 835-842.
Morrow              D.A. et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy // Circulation. - 2000. - Vol. 102. - P. 2031-2037.
Morrow              D.A. et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3 // JAMA. - 2001. - Vol. 286. - P. 1356-1359.
204.Singh M. et al. Scores for post-myocardial infarction risk stratification in the community // Circulation.
2002. - Vol. 106. - P. 2309-2314.
Lee              K.L. et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021. patients. GUSTO-I Investigators // Circulation. - 1995. - Vol. 91. - P. 1659-1668.
Hochman              J.S. et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? // J. Am. Coll. Cardiol. -
2000. - Vol. 36. (3. Suppl. A). - P. 1063-1070.
Lindholm M.G. et al. Cardiogenic shock complicating acute myocardial infarction. - prognostic impact of early and late shock development // Eur. Heart J. - 2003. - Vol. 24. - P. 258-265.
208.Schuchert A. et al. Prehospital testing for troponin T in patients with suspected acute myocardial infarction // Am. Heart J. - 1999. - Vol. 138. (1. Pt 1). - P. 45-48.
209.Richards A.M. et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction // Circulation. -
- Vol. 97. - P. 1921-1929.
210.Schroder R. et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction // J. Am. Coll. Cardiol. - 1994. - Vol. 24. - P. 384-391.
211.de Lemos J.A. et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST- elevation myocardial infarction. Observations from the TIMI 14. trial // Circulation. - 2000. - Vol. 101. - P. 239-243.
212.Smeeth L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination // N.
Engl. J. Med. - 2004. - Vol. 351. - P. 2611-2618.
Fedullo              PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism // N.
Engl. J. Med. - 2003. - Vol. 349. - P. 1247-1256.
James              P. et al. Relation between troponin T concentration and mortality in patients presenting with an acute // Stroke: observational study // BMJ. - 2000. - Vol. 320. - P. 1502-1504.
DePace              N.L. et al. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action // Arch. Intern. Med. - 1982. - Vol. 142. - P. 1806-1809.
Roubin              G.S. et al. Intravenous nitroglycerine in refractory unstable angina pectoris // Aust. N. Z. J. Med. - 1982. - Vol. 12. - P. 598-602.
Curfman              G.D. et al. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial // Circulation. - 1983. - Vol. 67. - P. 276-282.
Dellborg              M., Gustafsson G., Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris // Eur. J. Clin. Pharmacol. -
1991. - Vol. 41. - P. 5-9.
Theroux              P. et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina // J. Am. Coll. Cardiol. -
1985. - Vol. 5. - P. 717-722.
Lubsen              J., Tijssen J.G. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT) //
Am. J. Cardiol. - 1987. - Vol. 60. - P. 18A-25A.
Yusuf              S., Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification // JAMA. -
1988. - Vol. 260. - P. 2259-2263.
Metoprolol              in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group // Eur. Heart J. - 1985. - Vol. 6. - P. 199-226.
Kaplan              K. et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy // Am. J. Cardiol. - 1983. - Vol. 51. - P. 694-698.
Parodi              O. et al. Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit // Am. J. Cardiol. - 1986. - Vol. 57. - P. 899-906.
225.Smith N.L. et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 1305-1311.
Gibson R.S. et al. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study // Am. J. Cardiol. - 1987. - Vol. 60. - P. 203-209.
Held              P.H., Yusuf S., Furberg C.D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview // BMJ. - 1989. - Vol. 299. - P. 1187-1192.
Psaty              B.M. et al. The risk of myocardial infarction associated with antihypertensive drug therapies // JAMA. - 1995. - Vol. 274. - P. 620-625.
Yusuf              S., Held P., Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies // Am. J. Cardiol. - 1991. - Vol. 67. - P. 1295-1297.
Boden              W.E. et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) // Lancet. -
- Vol. 355. - P. 1751-1756.
Borer              J.S. Therapeutic effects of I(f) blockade: evidence and perspective // Pharmacol. Res. - 2006. - Vol. 53. - P. 440-445.
Effect              of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. - 2002. - Vol. 359. - P. 1269-1275.
Morrow              D.A. et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST- elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25. (ExTRACT-TIMI 25) trial // Am.
Heart J. - 2007. - Vol. 154. - P. 1078-841:084. e1.
McClellan              K.J., Plosker G.L. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions // Drugs. - 1999. - Vol. 58. - P. 143-157.
Chaitman              B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions // Circulation. - 2006. - Vol. 113. - P. 2462-2472.
Harrington              R.A. et al. Antithrombotic therapy for coronary artery disease:              the              Seventh ACCP
Conference on Antithrombotic and Thrombolytic Therapy // Chest. - 2004. - Vol. 126. (3. Suppl.). - P.513S-548S.
Hirsh              J. et al. Parenteral anticoagulants: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. - 2008. - Vol. 133. (6. Suppl.). - P. 141S-159S.
Bassand              J.P. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes // Eur. Heart J. - 2007. - Vol. 28. - P. 1598-660.
Eikelboom              J.W. et al. Unfractionated heparin and low-molecular-weight heparin              in              acute coronary
syndrome without ST elevation: a meta-analysis // Lancet. - 2000. - Vol. 355. - P. 1936-42.
Petersen              J.L. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview // JAMA. - 2004. - Vol. 292. - P. 89-96.
Yusuf              S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1464-1476.
Hurlen              M. et al. Warfarin: aspirin, or both after myocardial infarction // N. Engl. J. Med. - 2002. - Vol. 347. - P. 969-974.
Nguyen              M.C. et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? // Eur. Heart J. - 2007. - Vol. 28. - P. 1717-1722.
244.Silber S. et al. [Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC.]. Kardiol Pol. - 2005. - Vol. 63. - P. 265-320. - discussion 321-323.
245.Stone GW, et al. Bivalirudin for patients with acute coronary syndromes // N. Engl.              J.              Med. -              2006.              -
Vol. 355. - P. 2203-2216.
Ferguson              J.J. et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment
elevation acute coronary syndromes managed with an intended early invasive strategy: primary              results              of
the SYNERGY randomized trial // JAMA. - 2004. - Vol. 292. - P. 45-54.
Montalescot              G. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention // N. Engl. J. Med. - 2006. - Vol. 355. - P. 1006-1017.
Theroux              P. et al. Aspirin: heparin, or both to treat acute unstable angina // N. Engl. J. Med. - 1988. - Vol. 319. - P. 1105-11.
Theroux              P. et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina // Circulation. - 1993. -
Vol. 88. (5. Pt 1). - P. 2045-2048.
Cairns              J.A. et al. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000. people // Can. J. Cardiol. - 1989. - Vol. 5. - P. 239-246.
Collaborative              meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. - 2002. - Vol. 324. - P. 71-86.
Yusuf              S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation // N. Engl. J. Med. - 2001. - Vol. 345. - P. 494-502.
Gollapudi              R.R. et al. Aspirin sensitivity: implications for patients with coronary artery disease // JAMA.
2004. - Vol. 292. - P. 3017-3023.
Ramanuja              S., Breall J.A., Kalaria V.G. Approach to “aspirin allergy” in cardiovascular patients // Circulation. - 2004. - Vol. 110: e1-4.
Eikelboom              J.W. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events // Circulation. - 2002. -
Vol. 105. - P. 1650-165.
Balsano              F. et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group // Circulation. - 1990. - Vol. 82. - P. 17-26.
Budaj              A. et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment
elevation in various risk groups // Circulation. - 2002.              - Vol. 106. - P. 1622-1626.
Wiviott              S.D. et al. Prasugrel compared with high              loading- and maintenance-dose              clopidogrel              in
patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44. trial // Circulation. - 2007. - Vol. 116. - P. 2923-2932.
Fox              K.A. et al. Benefits and risks of the combination of clopidogrel and aspirin              in              patients undergoing
surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial // Circulation. - 2004. - Vol. 110. - P. 12021208.
Chan              A.W. et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) // J. Am. Coll. Cardiol. -
2003. - Vol. 42. - P. 1188-1195.
261.Steinhubl S.R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial // JAMA. - 2002. - Vol. 288. - P. 2411-2420.
262.Szuk T. et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes. - P. 300-mg loading dose immediately after coronary stenting versus pretreatment 6. to 24. hours before stenting in a large unselected patient cohort // Am. Heart J. - 2007. - Vol. 153. -
P. 289-295.
Kandzari              D.E. et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 2133-2136.
Montalescot              G. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial // J. Am. Coll. Cardiol. - 2006. - Vol. 48. -
P. 931-938.
Patti              G. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-
(Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study // Circulation. -
- Vol. 111. - P. 2099-2106.
von              Beckerath N. et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen. Choose Between 3. High Oral Doses for Immediate Clopidogrel Effect) Trial // Circulation. -
- Vol. 112. - P. 2946-2950.
Nguyen              T.A., Diodati J.G., Pharand C. Resistance to clopidogrel: a review of the evidence // J. Am. Coll. Cardiol. - 2005. - Vol. 45. - P. 1157-1164.
Geisler              T. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation // Eur. Heart J. - 2006. - Vol. 27. - P. 2420-2425.
Gurbel              PA. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity // Circulation. - 2003. - Vol. 107. - P. 2908-2913.
Matetzky              S. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction // Circulation. - 2004. - Vol. 109. - P. 3171-3175.
271.Saw J. et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial // Circulation. - 2003. - Vol. 108. - P. 921-924.
Lim              M.J. et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes perspectives from a large multinational registry // Eur. Heart J. - 2005. - Vol. 26. - P. 1063-1069.
Collet              J.P. et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes // Circulation. - 2004. -
Vol. 110. - P. 2361-2367.
Boersma              E. et al. Platelet glycoprotei